Monitor recipients of phosphodiesterase type 5 inhibitors for glaucoma, pending more clinical evidence of risk

AbstractGlaucoma is a leading cause of bilateral blindness. Phosphodiesterase type 5 inhibitors (PDE5Is; e.g. avanafil, sildenafil, tadalafil and vardenafil) may increase blood flow to the ciliary body, thereby elevating intraocular pressure and increasing the risk of glaucoma. PDE5Is are commonly used to treat erectile dysfunction, as well as benign prostatic hyperplasia (tadalafil) and pulmonary hypertension (sildenafil). Patients receiving PDE5Is require glaucoma education and ongoing screening, especially if they are taking a high dosage of a daily PDE5I or have risk factors for glaucoma (e.g. increased age, African-American or Hispanic race, hypertension, intraocular pressure  >  21 mm Hg, diabetes, suspicious eye changes or a family history of glaucoma).
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research

Related Links:

Researchers find that vaping may more than double the risk for erectile dysfunction.
Source: WebMD Health - Category: Consumer Health News Source Type: news
BACKGROUND A long-held goal of vision therapy is to transfer information directly to the visual cortex of blind individuals, thereby restoring a rudimentary form of sight. However, no clinically available cortical visual prosthesis yet exists.METHODS We implanted an intracortical microelectrode array consisting of 96 electrodes in the visual cortex of a 57-year-old person with complete blindness for a 6-month period. We measured thresholds and the characteristics of the visual percepts elicited by intracortical microstimulation.RESULTS Implantation and subsequent explantation of intracortical microelectrodes were carried o...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Insulin resistance is a cornerstone of obesity-related complications such as type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease. A high rate of lipolysis is known to be associated with insulin resistance, and inhibiting adipose tissue lipolysis improves obesity-related insulin resistance. Here, we demonstrate that inhibition of serotonin (5-hydroxytryptamine [5-HT]) signaling through serotonin receptor 2B (HTR2B) in adipose tissues ameliorates insulin resistance by reducing lipolysis in visceral adipocytes. Chronic high-fat diet (HFD) feeding increased Htr2b expression in epididymal white adipose tis...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Conditions:   Overweight and Obesity;   Child Obesity;   Hypertension;   NAFLD Interventions:   Dietary Supplement: Vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties;   Dietary Supplement: Vegetable and fruit mousse;   Behavioral: Dietary and physical activity counselling Sponsors:   Children's Memorial Health Institute, Poland;   Jan Dlugosz University of Czestochowa, Poland;   Tymbark MWS Sp. with o.o. Sp.&nb...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Diabetes Mellitus, Type 2;   Endothelial Dysfunction Interventions:   Drug: Dapagliflozin;   Other: Placebo Sponsors:   Boston University;   American Heart Association Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Bariatric Surgery Candidate Intervention:   Sponsor:   Imperial College London Diabetes Centre Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Metabolic-associated Fatty Liver Disease;   Type 2 Diabetes Interventions:   Drug: Empagliflozin;   Drug: Dulaglutide;   Drug: Empagliflozin and Dulaglutide Sponsor:   Seoul National University Bundang Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Drug Interactions;   Hypertension Intervention:   Sponsor:   Instituto Mexicano del Seguro Social Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Diabetes Mellitus, Type 1;   Eating Disorders Intervention:   Behavioral: STEADY intervention Sponsor:   King's College London Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Diabetes Mellitus;   Diabetes Mellitus, Type 2;   Diabetes Mellitus, Type 1;   Diabetes;   Depression;   Anxiety;   Distress, Emotional;   Diabetes Distress;   Loneliness;   Social Functioning;   Quality of Life Intervention:   Device: COMPASS: digital CBT Sponsors:   King's College London;   South London and Maudsley NHS trust Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Benign Prostatic Hyperplasia | Blindness | Cialis | Diabetes | Drugs & Pharmacology | Education | Endocrinology | Erectile Dysfunction | Glaucoma | Hypertension | Levitra | Opthalmology | Pulmonary Hypertension | Universities & Medical Training | Viagra